NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov
Benchmarks Nifty22,811.35-77.61FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.7 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.39 % Invest NowEnter search…
India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. This cap, effective from November 9, applies to all listed drugs, including Atezolizumab and Bevacizumab. Manufacturers must adjust prices if they exceed the newly calculated maximum retail price. Compliance will be monitored by state drug controllers and hospitals, which play a significant role in drug supply.
Listen to this article in summarized format
Loading...×India’s drug pricing authority-National Pharmaceutical Pricing Authority (NPPA) on Saturday capped trade margins on extensively used 137 anti-cancer drugs at 30 per cent of MRP, with the revised prices set to take effect from November 9.The list of 137 drugs has been recommended by an expert committee of the Union health ministry and includes extensively used drugs like-Atezolizumab, Bevacizumab, Daratumumab, Enzalutamide, Erlotinib, Ipilimumab, Lapatanib, pembrolizumab, among others.
The 30% cap on trade margins, calculated on the maximum retail price (MRP) excluding GST, corresponds to a mark-up of 42.86% on the price to stockist or distributor.
Also Read | Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possible
The cap will apply irrespective of the strength, dosage form or route of administration, including formulations containing the drugs in combination, the NPPA said.
Live Events
Under the approved mechanism, the revised MRP will be calculated using the price to stockist or distributor for March 2026 as the reference. Where a formulation had no sales during that month, the price will be calculated using sales data for April 2025 to March 2026. Government sales will be excluded from the calculation.
Manufacturers selling medicines above the newly calculated MRP will have to reduce prices to the prescribed level. If an existing MRP is already lower, it must be maintained, the NPPA said. The order will remain in force until further directions, while manufacturers can continue to avail themselves of annual price increases permitted under the DPCO, subject to compliance with the trade-margin cap.
Also Read | Biocon clears path for cancer drug launch
The order also covers formulations launched after March 31, 2026, containing any of the listed drugs. Where manufacturers supply medicines directly to hospitals or medical institutions, these institutions will be treated as stockists or distributors for the purpose of calculating the MRP, using the manufacturers’ invoice data.
The authority has also directed manufacturers to maintain current production levels to ensure uninterrupted availability of the covered medicines. “Any manufacturer intending to reduce average monthly production levels shall obtain prior permission from NPPA, the minutes said.
Manufacturers intending to discontinue production or imports must provide the prescribed information at least six months in advance.
The NPPA has allowed a limited exclusion for quantities supplied free of cost to patients under manufacturers’ patient assistance programmes. However to qualify manufacturers will submit an undertaking and maintain detailed records of patients, prescriptions, drug supplies and consumption.
The authority can seek further information, conduct audits and inspections, and verify implementation. Non-compliance could lead to the exemption being withdrawn.
Manufacturers will have to submit revised MRP information to the NPPA and the concerned state drug controller within seven days of publication of the order in the Official Gazette, even if there is no change in the MRP. They must also issue the prescribed price lists through the Integrated Pharmaceutical Database Management System and provide copies to state drug controllers, dealers and other entities as required.
Failure to submit the required information will be treated as non-reduction of MRP and may trigger action to recover overcharged amounts under the DPCO.
Hospitals and medical institutions, which account for a substantial share of anti-cancer drug supplies have been asked to monitor MRPs and report violations to the NPPA. State drug controllers will oversee compliance by manufacturers, dealers, hospitals and medical institutions.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
( Originally published on Oct 17, 2026 )Read More News onNPPA cancer drug price captrade margin cancer drugscancer drug list IndiaDPCO guidelines for drug pricingrevised MRP cancer medicationsNPPA compliance hospitalsNational Pharmaceutical Pricing Authoritynppa
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...moreless(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onNPPA cancer drug price captrade margin cancer drugscancer drug list IndiaDPCO guidelines for drug pricingrevised MRP cancer medicationsNPPA compliance hospitalsNational Pharmaceutical Pricing Authoritynppa
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...morelessContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET
Unlock Access to All Exclusives with ETPrime FREE TRIAL
15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers
Trial offer expiring in00 : 05 : 00
I'd rather pay ₹2599 nowUh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Prime Account Detected!
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.
Unlock ETPrime's Exclusive Stories Today!
Big Price Drop! Flat 40% Off
Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In nowOffer Exclusively For You
Save up to Rs. 700/-
ON ET PRIME MEMBERSHIP
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get Flat 40% Off
Then ₹ 1749 for 1 year
Avail OfferOffer Exclusively For You
ET Prime at ₹ 49 for 1 month
Then ₹ 1749 for 1 year
Avail OfferSpecial Offer
Get flat 40% off on ETPrime
Avail OfferAvail OfferClaim NowAlready a Member? Sign In nowNeed Assistance?
Connect with an ETPrime expert for personalized support and guidance
+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '' + h3 + '
' + h4 + '
- ' + listing + '
What’s Included with
ETPrime Membership
1Exclusive Insights That Matter
Uncover the truth with our investigative stories
Make strategic moves using the real-world case studies
Read industry-specific stories to identify emerging trends
Spot opportunities with in-depth insights that matter
Trump temper on H-1B visas is forcing Indians to do these things to stay put in US
What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.
Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?
The problem with lab grown diamonds
Why a falling rupee is a better option for the economy
A list of top 20 momentum stocks that have delivered massive returns in one year
2Invest Wisely With Smart Market Tools & Investment Ideas
Alpha Trade
Get daily trade ideas from SEBI-registered research analysts.
Investment Ideas
Grow your wealth with stock ideas & sectoral trends.
Stock Reports Plus
All-in-one stock research with Stock Score, peer comparison & key signals.
BigBull Portfolio
Get to know where the market bulls are investing to identify the right stocks.
Stock Analyzer
Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.
Market Mood
Analyze the market sentiments & identify the trend reversal for strategic decisions.
Stock Talk Live at 9 AM Daily
Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.
3Stay informed anytime, anywhere with ET ePaper
ePaper - Print View
Read the PDF version of ET newspaper. Download & access it offline anytime.
ePaper - Digital View
Read your daily newspaper in Digital View & get it delivered to your inbox everyday.
Wealth Edition
Manage your money efficiently with this weekly money management guide.
TOI ePaper
Read the PDF version of TOI newspaper. Download & access it offline anytime.
Deep Explainers
Explore the In-depth explanation of complex topics for everyday life decisions.
Health+ Stories
Get fitter with daily health insights committed to your well-being.
Personal Finance+ Stories
Manage your wealth better with in-depth insights & updates on finance.
5Enjoy Complimentary Subscriptions From Top Brands
Stream new documentaries from all across the world every day.
Stories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
